WO2018064964A1 - 半胱氨酸改造的抗体-毒素偶联物及其制备方法 - Google Patents
半胱氨酸改造的抗体-毒素偶联物及其制备方法 Download PDFInfo
- Publication number
- WO2018064964A1 WO2018064964A1 PCT/CN2017/104706 CN2017104706W WO2018064964A1 WO 2018064964 A1 WO2018064964 A1 WO 2018064964A1 CN 2017104706 W CN2017104706 W CN 2017104706W WO 2018064964 A1 WO2018064964 A1 WO 2018064964A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cysteine
- pab
- mmae
- tdc
- Prior art date
Links
- 235000018417 cysteine Nutrition 0.000 title claims abstract description 54
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 12
- 238000003780 insertion Methods 0.000 claims abstract description 30
- 230000037431 insertion Effects 0.000 claims abstract description 30
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 9
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract description 5
- 239000002619 cytotoxin Substances 0.000 claims abstract description 5
- 101710112752 Cytotoxin Proteins 0.000 claims abstract description 4
- 238000005277 cation exchange chromatography Methods 0.000 claims description 22
- 230000008878 coupling Effects 0.000 claims description 19
- 238000010168 coupling process Methods 0.000 claims description 19
- 238000005859 coupling reaction Methods 0.000 claims description 19
- 239000002596 immunotoxin Substances 0.000 claims description 15
- 150000001413 amino acids Chemical group 0.000 claims description 14
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 3
- WMAXWOOEPJQXEB-UHFFFAOYSA-N 2-phenyl-5-(4-phenylphenyl)-1,3,4-oxadiazole Chemical compound C1=CC=CC=C1C1=NN=C(C=2C=CC(=CC=2)C=2C=CC=CC=2)O1 WMAXWOOEPJQXEB-UHFFFAOYSA-N 0.000 claims description 3
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 3
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 238000012412 chemical coupling Methods 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 abstract description 5
- 150000003384 small molecules Chemical class 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 63
- NLMBVBUNULOTNS-HOKPPMCLSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o Chemical compound C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN3C(C=CC3=O)=O)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 NLMBVBUNULOTNS-HOKPPMCLSA-N 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 33
- 238000001514 detection method Methods 0.000 description 25
- 239000000203 mixture Substances 0.000 description 23
- 229920002684 Sepharose Polymers 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 11
- 229940127121 immunoconjugate Drugs 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 10
- KRHAHEQEKNJCSD-UHFFFAOYSA-N Dihydroasparagusic acid Natural products OC(=O)C(CS)CS KRHAHEQEKNJCSD-UHFFFAOYSA-N 0.000 description 10
- 239000012515 MabSelect SuRe Substances 0.000 description 10
- JYGAZEJXUVDYHI-UHFFFAOYSA-N dihydroartemisininic acid Natural products C1CC(C)=CC2C(C(C)C(O)=O)CCC(C)C21 JYGAZEJXUVDYHI-UHFFFAOYSA-N 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 8
- 238000011835 investigation Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JPJMNCROLRPFHI-QFIPXVFZSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoate Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)ON1C(=O)CCC1=O JPJMNCROLRPFHI-QFIPXVFZSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- HYSPJPGXSALJRR-DHIFEGFHSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(COC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O HYSPJPGXSALJRR-DHIFEGFHSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FBVVGPMIPAZFAW-RZVRUWJTSA-N (2S)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H]1CCCN1 FBVVGPMIPAZFAW-RZVRUWJTSA-N 0.000 description 1
- KUNFMZSTKSLIEY-GRHHLOCNSA-N (2s)-2-azanyl-3-phenyl-propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 KUNFMZSTKSLIEY-GRHHLOCNSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VDJKJPMLWJWQIH-UHFFFAOYSA-M 5-ethylphenazin-5-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.C1=CC=C2[N+](CC)=C(C=CC=C3)C3=NC2=C1 VDJKJPMLWJWQIH-UHFFFAOYSA-M 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N Alanyl-alanine Chemical compound CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- AMKBTTRWLGVRER-OFVILXPXSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(CO)cc1)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(CO)cc1)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O AMKBTTRWLGVRER-OFVILXPXSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N O=C(CCCCCN(C(C=C1)=O)C1=O)ON(C(CC1)=O)C1=O Chemical compound O=C(CCCCCN(C(C=C1)=O)C1=O)ON(C(CC1)=O)C1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- -1 tetrazolium compound Chemical class 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to a compound and a process for the preparation thereof, and in particular to a cysteine engineered antibody-toxin conjugate and a process for the preparation thereof.
- ADC Antibody-conjugates
- the cysteine insertion site comprises one or more sites selected from the following three insertion sites: light chain position 205 ( Kabat number, its amino acid sequence is GLSSP C VTKSF), light chain position 206 (Kabat number, its amino acid sequence is GLSSPV C TKSF), heavy chain position 439 (Kabat number, its amino acid sequence is YTQKSLS C LSPGK).
- An antibody comprising one or more of the above cysteine insertion mutations retains the ability (affinity) of binding of the parent antibody to the antigen.
- the present invention performs site-directed coupling of antibody-toxin conjugate (TDC) with a linker-drug by a cysteine thiol group inserted at position 205 or/and position 206 of the light chain or/and position 439 of the heavy chain.
- TDC antibody-toxin conjugate
- the antibody is a cysteine site-incorporated antibody
- the cysteine insertion site comprises one or more sites selected from the following three insertion sites: kappa/ ⁇ light chain
- the constant region was at position 205 (Kabat numbering)
- the light chain constant region was at position 206 (Kabat numbering)
- the IgG antibody heavy chain constant region was at position 439 (Kabat numbering).
- the cysteine insertion site amino acid sequence comprises one or more of the following three sequences: LC-205ins: GLSSP C VTKSF; LC-206ins: GLSSPV C TKSF or HC-439ins: TQKSLS C LSPGK.
- the highly active cytotoxin is site-coupled to the inserted cysteine free thiol (-SH) via a linker.
- the linker is coupled to the inserted cysteine.
- the light chain amino acid sequence of the antibody is: GLSSP C VTKSF and GLSSPV C TKSF
- the amino acid sequence of the linker and the inserted cysteine-conjugated antibody heavy chain is: TQKSLS C LSPGK, wherein C is the cysteine inserted at position 205 or position 206 of the target antibody light chain or position 439 of the heavy chain .
- said antibody light chain comprises a kappa or lambda isoform.
- the antibody heavy chain comprises an IgGl, IgG2, IgG3 or IgG4 isotype.
- cysteine comprises a thiol group (-SH).
- the thiol group (-SH) is capable of chemical coupling.
- the small molecule highly active cytotoxins that are site-coupled by a linker with a cysteine insertion mutant free sulfhydryl group include, but are not limited to, MMAE, MMAF, PBD, SN-38, Dox, and the like, MMAE, MMAF , PBD, SN-38 and Dox molecular formula are:
- the main site-directed coupling step is: first reducing the antibody with a reducing agent (such as DTT, TCEP, etc.), removing the shielding on the modified cysteine residue on the antibody, and removing it by cation exchange chromatography or ultrafiltration.
- a reducing agent such as DTT, TCEP, etc.
- the DTT is shielded and then oxidized with an oxidizing agent (such as DHAA, CuSO4, etc.) to religate the interchain disulfide bonds of the antibody.
- Linker-drug is coupled to the free sulfhydryl group on the cystine residue, and the unconjugated antibody molecule Linker- is removed by cation exchange chromatography or ultrafiltration exchange. Drug.
- GLSSP C VTKSFN sequence to mark the point C of conjugation sites, site-directed coupling with mc-vc-PAB-payload.
- GLSSPV C TKSFN sequence to mark the point C of conjugation sites, site-directed coupling with mc-vc-PAB-payload.
- TQKSLS C LSPGK sequence to mark the point C of conjugation sites, site-directed coupling with mc-vc-PAB-payload.
- GLSSP C TKSFN sequence to mark the point C of conjugation sites, site-directed coupling with mc-vc-PAB-payload.
- TDC novel cysteine-modified antibody-toxin conjugate
- Figure 1 is a graph showing the results of HIC-HPLC detection of 2A1-LC-Cys205ins-mc-vc-PAB-MMAE in Example 25.
- FIG. 2 is a graph showing the results of HIC-HPLC detection of 2A1-LC-Cys206ins-mc-vc-PAB-MMAE in Example 25.
- Figure 3 is a graph showing the results of HIC-HPLC detection of 2A1-HC-Cys439ins-mc-vc-PAB-MMAE in Example 25.
- Figure 4 is a graph showing the results of HIC-HPLC detection of 4E1-LC-Cys205ins-mc-vc-PAB-MMAE in Example 25.
- Figure 5 is a graph showing the results of HIC-HPLC detection of 4E1-LC-Cys206ins-mc-vc-PAB-MMAE in Example 25.
- Figure 6 is a graph showing the results of HIC-HPLC detection of 4E1-HC-Cys439ins-mc-vc-PAB-MMAE in Example 25.
- Figure 7 is a graph showing the results of HIC-HPLC detection of 4D3-LC-Cys205ins-mc-vc-PAB-MMAE in Example 25.
- Figure 8 is a graph showing the results of HIC-HPLC detection of 4D3-LC-Cys206ins-mc-vc-PAB-MMAE in Example 25.
- Figure 9 is a graph showing the results of RP-HPLC detection of the ratio of 4D3-HC-Cys439ins-mc-vc-PAB-MMAE toxin to antibody in Example 26.
- Fig. 10 is a graph showing the results of aggregation of TDC antibody skeleton 4D3 by SEC-HPLC in Example 27.
- Figure 11 is a graph showing the results of aggregation of TDC antibody backbone 4D3-LC-Cys205ins by SEC-HPLC in Example 27.
- Figure 12 is a graph showing the results of aggregation of TDC antibody backbone 4D3-LC-Cys206ins by SEC-HPLC in Example 27.
- Figure 13 is a graph showing the results of aggregation of TDC antibody backbone 4D3-HC-Cys439ins by SEC-HPLC in Example 27.
- Figure 14 is a graph showing the results of the experiment in Example 28.
- Figure 15 is a graph showing the results of affinity of 4E1-LC-Cys205ins-MVPM, 4E1-LC-Cys206ins-MVPM, 4E1-HC-Cys439ins-MVPM antibody and antigen c-met in Example 29.
- Figure 16 is a graph showing the results of affinity of TDC 4D3-LC-Cys205ins-MVPM, 4D3-LC-Cys206ins-MVPM, 4D3-HC-Cys439ins-MVPM antibody and antigen Trop2 in Example 29.
- Figure 17 is 2A1-LC-V205C-mc-vc-PAB-MMAE, 2A1-LC-Cys205ins-mc-vc-PAB-MMAE, 2A1-LC-Cys206ins-mc-vc-PAB-MMAE, 2A1-HC-Cys439ins -mc-vc-PAB-MMA
- Figure 18 is 2A1-LC-V205C-mc-vc-PAB-MMAE, 2A1-LC-Cys205ins-mc-vc-PAB-MMAE, 2A1-LC-Cys206ins-mc-vc-PAB-MMAE, 2A1-HC-Cys439ins -mc-vc-PAB-MMAE
- IC50 detection of human glioma cell line U87-EGFRvIII overexpressing FGRvIII The results of IC50 detection of human glioma cell line U87-EGFRvIII overexpressing FGRvIII.
- Figure 19 is 4E1-LC-Cys205ins-mc-vc-PAB-MMAE, 4E1-LC-Cys206ins-mc-vc-PAB-MMAE, 4E1-HC-Cys439ins-mc-vc-PAB-MMAE, 4E1 vs. c-Met
- Figure 20 is a high expression of trop2 by D3-LC-Cys205ins-mc-vc-PAB-MMAE, 4D3-LC-Cys206ins-mc-vc-PAB-MMAE, 4D3-HC-Cys439ins-mc-vc-PAB-MMAE, 4D3 Figure 50 shows the results of IC50 detection of pancreatic cancer cell line BXPC-3.
- Figure 21 is a graph showing the results of investigation of the stability of 4D3-LC-Cys205ins-mc-vc-PAB-MMAE in human plasma.
- Figure 22 is a graph showing the results of investigation of the stability of 4D3-LC-Cys206ins-mc-vc-PAB-MMAE in human plasma.
- Figure 23 is a graph showing the results of investigation of the stability of 4D3-HC-Cys439ins-mc-vc-PAB-MMAE in human plasma.
- Figure 24 is a graph showing the results of investigation of the stability of 4E1-LC-Cys205ins-mc-vc-PAB-MMAE in human plasma.
- Figure 25 is a graph showing the results of investigation of the stability of 4E1-LC-Cys206ins-mc-vc-PAB-MMAE in human plasma.
- Figure 26 is a graph showing the results of investigation of the stability of 4E1-HC-Cys439ins-mc-vc-PAB-MMAE in human plasma.
- Figure 27 is a 4D3-LC-Cys205ins-mc-vc-PAB-MMAE, 4D3-LC-Cys206ins-mc-vc-PAB-MMAE, 4D3-HC-Cys439ins-mc-vc-PAB-MMAE, 4D3 parent antibody The results of the test results of tumor mice.
- Figure 28 is a 4D3-LC-Cys205ins-mc-vc-PAB-MMAE, 4D3-LC-Cys206ins-mc-vc-PAB-MMAE, 4D3-HC-Cys439ins-mc-vc-PAB-MMAE, 4D3 parent antibody The results of the test results of tumor mice.
- Fmoc-vc-PABOH 490 mg (0.815 mmol) was added to 10 ml of NMP and stirred to dissolve, and then 2 ml of diethylamine was added. The reaction was stirred at room temperature for 24 h. After completion of the reaction, the mixture was concentrated under reduced pressure at 40 ° C. EtOAc (EtOAc) m/z: 380.2 (M+H)+.
- VP-PABOH 205 mg (0.54 mmol) and MC-OSu 184 mg (1.1 eq) were added to 10 ml of NMP, and the reaction was stirred at room temperature for 24 h. After completion of the reaction, the mixture was concentrated under reduced pressure at 40 ° C. Filtration and washing of the cake with methyl tert-butyl ether afforded 310 mg of product in 100% yield. m/z: 573.3 (M+H)+.
- Example 9 According to the operation of Example 9, about 12.5 mg of mc-vc-PAB-MMAF was obtained, yield 45.2%, m/z: 1345.7 (M+H)+.
- Example 9 According to the operation of Example 9, 9.5 mg of mc-vc-PAB-PBD was obtained in a yield of 32.5%, m/z: 1325.4 (M+H)+.
- Example 9 According to the operation of Example 9, about 11.2 mg of mc-vc-PAB-DOX was obtained, yield 38.9%, m/z: 1143.2 (M+H)+.
- Use Freestyle TM 293-F was suspended cells expressing the antibody.
- cells were seeded at a density of 6 ⁇ 105 cells/mL in a 1 L shake flask containing 300 mL of F17 complete medium (FreestyleTM F17 expression medium, Gibco), shaken at 37 ° C, 5% CO 2 , 120 rpm. The bed was incubated overnight.
- transfection of the antibody expression plasmid was carried out with PEI, wherein the ratio of plasmid: PEI was 2:1.
- the TN1 feed medium was added at 2.5% (v/v), and the culture was continued for 4 days, and the supernatant was collected by centrifugation.
- the collected cell expression supernatant was eluted by a Protein A affinity chromatography column (Mabselect Sure LX, GE) eluting with 0.1 M citric acid (pH 3.0), and the captured antibody was treated with 1 M Tris-HCl (pH 9.0). Adjust to pH 7.0 at 1/10 (v/v), and remove impurities such as multimers and endotoxin by gel filtration column SEC (Superdex 200, GE), and replace the antibody buffer with PBS. (pH 7.4), a sample of the target peak of UV280 nm was collected and concentrated to 2 mg/ml through an ultrafiltration centrifuge tube (30 KD, Pall Corporation). The target antibody monomer (POI%) obtained by this method was greater than 90% for subsequent experiments.
- the 2A1-HC-Cys439ins antibody expressed by the cells was purified by Mabselect Sure, and immediately after the low pH elution, it was neutralized by adding Tris solution, and the solution was changed to a pH 7.5 Tris-HCl buffer.
- Compound mc-vc-PAB-MMAE, white powder, was dissolved in DMA for use. In order to remove the shield on the mutant cysteine residue, the antibody needs to be reduced first.
- a 1 M aqueous solution of DTT was added to the 2A1-HC-Cys439ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0, and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography.
- the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds.
- mc-vc-PAB-MMAE solution was added to couple mc-vc-PAB-MMAE with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the 2A1-LC-Cys205ins antibody expressed by the cells was purified by Mabselect Sure, and immediately after the low pH elution, it was neutralized by adding Tris solution, and the solution was changed to a pH 7.5 Tris-HCl buffer.
- a 1 M aqueous solution of DTT was added to the 2A1-LC-Cys205ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0, and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography.
- the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds.
- mc-vc-PAB-MMAE solution was added to couple mc-vc-PAB-MMAE with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the 2A1-LC-Cys206ins antibody expressed by the cells was purified by Mabselect Sure, and immediately after the low pH elution, it was neutralized by adding Tris solution, and the solution was changed to a pH 7.5 Tris-HCl buffer.
- Compound mc-vc-PAB-MMAE, white powder, was dissolved in DMA for use. In order to remove the shield on the mutant cysteine residue, the antibody needs to be reduced first.
- a 1 M aqueous solution of DTT was added to the 2A1-LC-Cys206ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0, and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography.
- the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds.
- mc-vc-PAB-MMAE solution was added to couple mc-vc-PAB-MMAE with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the 4D3-HC-Cys439ins antibody expressed by the cells was purified by Mabselect Sure, immediately after low pH elution, and added to Tris solution for neutralization, and the solution was changed to pH 7.5 Tris-HCl buffer.
- Compound mc-vc-PAB-MMAE, white powder, was dissolved in DMA for use. In order to remove the shield on the mutant cysteine residue, the antibody needs to be reduced first.
- a 1 M aqueous solution of DTT was added to the 4D3-HC-Cys439ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0 and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography. Subsequently, the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds. Then, mc-vc-PAB-MMAE solution was added to couple mc-vc-PAB-MMAE with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the 4D3-LC-Cys205ins antibody expressed by the cells was purified by Mabselect Sure, and immediately after neutralization with low pH, neutralized with Tris solution, and changed to a pH 7.5 Tris-HCl buffer.
- Compound mc-vc-PAB-MMAE, white powder, was dissolved in DMA for use. In order to remove the shield on the mutant cysteine residue, the antibody needs to be reduced first.
- a 1 M aqueous solution of DTT was added to the 4D3-LC-Cys205ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0, and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography.
- the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds.
- mc-vc-PAB-MMAE solution was added to couple mc-vc-PAB-MMAE with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the 4D3-LC-Cys206ins antibody expressed by the cells was purified by Mabselect Sure, and immediately after the low pH elution, the Tris solution was neutralized and the solution was changed to a pH 7.5 Tris-HCl buffer.
- Compound mc-vc-PAB-MMAE, white powder, was dissolved in DMA for use. In order to remove the shield on the mutant cysteine residue, the antibody needs to be reduced first.
- a 1 M aqueous solution of DTT was added to the 4D3-LC-Cys206ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0, and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography.
- the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds.
- mc-vc-PAB-MMAE solution so that mc-vc-PAB-MMAE was coupled with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the 4E1-HC-Cys439ins antibody expressed by the cells was purified by Mabselect Sure, and immediately after the low pH elution, it was neutralized by adding Tris solution, and the solution was changed to a pH 7.5 Tris-HCl buffer.
- Compound mc-vc-PAB-MMAE, white powder, was dissolved in DMA for use. In order to remove the shield on the mutant cysteine residue, the antibody needs to be reduced first.
- a 1 M aqueous solution of DTT was added to the 4E1-HC-Cys439ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0, and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography.
- the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds.
- mc-vc-PAB-MMAE solution was added to couple mc-vc-PAB-MMAE with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the 4E1-LC-Cys205ins antibody expressed by the cells was purified by Mabselect Sure, immediately after the low pH elution, and added to the Tris solution for neutralization, and the solution was changed to a pH 7.5 Tris-HCl buffer.
- Compound mc-vc-PAB-MMAE, white powder, was dissolved in DMA for use. In order to remove the shield on the mutant cysteine residue, the antibody needs to be reduced first.
- a 1 M aqueous solution of DTT was added to the 4E1-LC-Cys205ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0, and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography.
- the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds.
- mc-vc-PAB-MMAE solution was added to couple mc-vc-PAB-MMAE with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the 4E1-LC-Cys206ins antibody expressed by the cells was purified by Mabselect Sure, and immediately after low pH elution, it was added to Tris solution for neutralization, and the solution was changed to pH 7.5 Tris-HCl buffer.
- Compound mc-vc-PAB-MMAE, white powder, was dissolved in DMA for use. In order to remove the shield on the mutant cysteine residue, the antibody needs to be reduced first.
- a 1 M aqueous solution of DTT was added to the 4E1-LC-Cys206ins antibody solution at a molecular ratio of 40 times, and the mixture was reacted at 20 ° C for 2 hours.
- the pH of the sample was adjusted to 5.0, and the DTT and the shield in the sample were removed by SP Sepharose F.F. cation exchange chromatography.
- the DHAA solution was added to the sample at a molecular ratio of 20 times, and reacted at 25 ° C for 4 hours in the dark to recombine the interchain disulfide bonds.
- mc-vc-PAB-MMAE solution was added to couple mc-vc-PAB-MMAE with the antibody mutant cysteine, and the mixture was thoroughly mixed and reacted at 25 ° C for 2 hours.
- the TDC sample was analyzed by high performance liquid chromatography with hydrophobic chromatography and DAR was calculated from the corresponding peak area.
- the specific method is as follows:
- Mobile phase A: 2M ammonium sulfate, 0.025 M, pH 7 phosphate buffer; B: 0.025 M, pH 7 phosphate buffer; C: 100% isopropanol;
- Buffer A equilibrated, buffer B and buffer C gradient elution, detection at 25 ° C, 214 nm and 280 wavelengths.
- the fixed-point coupled DAR is calculated to be between 1.6 and 1.7, and the compound uniformity is good.
- the fixed-point coupled DAR is calculated to be between 1.60-1.95, and the compound uniformity is very good.
- the fixed-point coupled DAR is calculated between 1.60-1.90, and the compound uniformity is very good.
- the ratio of toxin to antibody was measured by RP-HPLC.
- the sample treated with DTT was analyzed by reversed-phase hydrophobic high performance liquid chromatography, and DAR was calculated from the corresponding peak area.
- the specific method is as follows:
- Mobile phase A and mobile phase B were eluted in a proportional gradient at 80 ° C, 214 nm and 280 wavelengths.
- the fixed-point coupled DAR was calculated to be 1.82, and the compound uniformity was excellent.
- Table 1 shows that the coupling efficiency of site-directed TDC compounds by cysteine insertion mutation modification is high (theoretical maximum is 2.0), DAR ⁇ 1.6.
- TDC antibody skeleton samples were stored at 37 ° C, and their aggregation was analyzed by SEC-HPLC on days 0, 7, 21, and 29, respectively.
- SEC-HPLC SEC-HPLC on days 0, 7, 21, and 29, respectively.
- Mobile phase 0.1 M sodium sulfate, 0.1 M, pH 6.7 phosphate buffer.
- SEC-HPLC was used to detect the aggregation of TDC antibody backbones 4D3, 4D3-LC-Cys205ins, 4D3-LC-Cys206ins and 4D3-HC-Cys439ins.
- the samples were stored at 37 ° C for 4 weeks, and the aggregate content remained basically unchanged. .
- Table 2 shows that the target monomer content of the TDC compound coupled by cysteine is above 90%.
- Example 28 Skeletal antibody and parental antibody 2A1 modified by cysteine site-directed mutagenesis and insertional mutagenesis Affinity for EGFRvIII, affinity of 4E1 for c-met, affinity of 4D3 for Trop2.
- Recombinant EGFRvIII-His*6 antigen-coated plate fish skin gelatin blocked; diluted 2A1, 2A1-LC-V205C, 2A1-LC-Cys205ins, 2A1-LC-Cys206ins and 2A1-HC-Cys439ins, respectively, the highest concentration 10ug/ml, 4 Dilute gradient dilution, a total of 11 concentrations; HRP-labeled secondary antibody incubation; TMB coloration, detection of absorption at 450 nm.
- 2A1-LC-V205C, 2A1-LC-Cys205ins, 2A1-LC-Cys206ins, 2A1-HC-Cys439ins antibodies retained the affinity of 2A1 to the antigen EGFRvIII.
- Example 29 Affinity of a backbone antibody engineered with a cysteine site-directed mutagenesis and an insertional mutation and TDC for the corresponding antigen. 4E1 affinity for c-met, 4D3 affinity for Trop2.
- Recombinant c-met-His*10 antigen-coated plate fish skin gelatin closed; diluted 4E1-LC-Cys205ins-MVPM, 4E1-LC-Cys206ins-MVPM, 4E1-HC-Cys439ins-MVPM and 4E1, respectively, the highest concentration 10ug/ml , 4 times gradient dilution, a total of 11 concentrations; HRP-labeled secondary antibody incubation; TMB coloration, detection of absorption at 450 nm.
- 4E1-LC-Cys205ins-MVPM, 4E1-LC-Cys206ins-MVPM, 4E1-HC-Cys439ins-MVPM antibodies retained the affinity of 4E1 for antigen c-met.
- 4D3-LC-Cys205ins-MVPM, 4D3-LC-Cys206ins-MVPM, 4D3-HC-Cys439ins-MVPM antibodies maintained the affinity of 4D3 for the antigen Trop2.
- TDC cytotoxic activity was determined by the following experimental procedure: TDC was separately added to human tumor cell culture medium in which EGFR was overexpressed or EGFRVIII was expressed, and cell viability was measured after 72 hours of cell culture. Cell-based in vitro assays were used to determine cell viability, cytotoxicity, and TDC-induced apoptosis in the present invention.
- CellTiter Solution Cell Proliferation Assay is commercially available (Promega Corp., Madison, WI).
- CellTiter AQueous One Solution Cell Proliferation Assay (a) is a detection reagent for colorimetric detection of the number of viable cells in cell proliferation and cytotoxicity experiments.
- This reagent contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and An electronic coupling agent (phenazine ethosulfate; PES).
- PES has enhanced chemical stability which allows it to be mixed with MTS to form a stable solution.
- This convenient "single solution" mode is in the first generation of CellTiter Improvements based on Assay, CellTiter
- the electron coupling agent PMS used in Assay is supplied separately from the MTS solution.
- MTS (Owen's reagent) is biologically reduced to a colored formazan product that is directly soluble in the medium ( Figure 1). This transformation is most likely accomplished by the action of NADPH or NADH produced by dehydrogenase in metabolically active cells.
- NADPH NADPH
- NADH NADH
- the amount of formazan product detected at 490 nm is directly proportional to the number of viable cells in the culture. Since the MTS hyperthyroid product is soluble in tissue culture medium, CellTiter The AQueous One Solution Assay has fewer steps than the MTT or INT method.
- A431 EGFR overexpressing cells
- U87-EGFRVIII EGFR mutant stable cell line
- U87-MG highly expressed glioblastoma cell line in c-Met
- BXPC-3 high expression of trop2
- the pancreatic cancer cell line is used as a research system for in vitro drug efficacy testing.
- cell plating was performed at 6000/well, and after 24 hours, antibody administration was performed.
- the initial concentrations of various TDCs corresponding to A431, U87-EGFRVIII cell lines were 10 uM, which were sequentially diluted according to a 5-fold gradient.
- the initial concentrations of various TDCs corresponding to U87-MG and BXPC-3 cell lines were 1 uM, which were sequentially diluted according to a 5-fold gradient.
- MTS assayed for cell activity after 72 hours of treatment.
- ADC sample Take a certain amount of ADC sample, add it to human plasma with human IgG removed, repeat 2 tubes of each ADC, incubate in 37 °C water bath, incubate for 0h, 72h, take ADC samples, add ProteinA (MabSelect) SuReTM LX Lot: #10221479GE, washed with PBS 100 ul, shaken by a vertical mixer for 2 h, and subjected to a washing and elution step to obtain an ADC after incubation.
- the ADC samples of the specific time of incubation were subjected to HIC-HPLC and RP-HPLC to determine the plasma stability of the samples.
- TDC was relatively stable after being incubated at 37 ° C for 72 hours in human plasma samples, and had good drug-forming properties.
- TDC with 439 insertion mutations had the best stability, followed by TDC with 205 and 206 insertion mutations.
- a BXPC-3 tumor-bearing mouse model was established to evaluate the in vivo efficacy of TDC and parental antibodies. That is, 3 ⁇ 106 BXPC-3 cells were subcutaneously injected into the back side of 4-8 weeks old BALB/c nude mice, and the average tumor size of the mice was grown to 400-500 mm3, randomly grouped, 5 rats in each group.
- 4D3-LC-Cys205ins-mc-vc-PAB-MMAE TDC, 4D3-LC-Cys206ins-mc-vc-PAB-MMAE TDC and 4D3-HC-Cys439ins-mc-vc-PAB-MMAE TDC was administered in a single intravenous dose at a dose of 5 mg/kg, and the parent antibody 4D3 was administered at a dose of 5 mg/kg.
- Data A is shown as the mean tumor volume ⁇ SE at the time of measurement
- data B is shown as the average body weight of the mouse at the time of measurement ⁇ SE.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
中文名称 | 英文名称 | 符号与缩写 |
丙氨酸 | Alanine | A或Ala |
精氨酸 | Arginine | R或Arg |
天冬酰胺 | Asparagine | N或Asn |
天冬氨酸 | Aspartic acid | D或Asp |
半胱氨酸 | Cysteine | C或Cys |
谷氨酰胺 | Glutamine | Q或Gln |
谷氨酸 | Glutamic acid | E或Glu |
甘氨酸 | Glycine | G或Gly |
组氨酸 | Histidine | H或His |
异亮氨酸 | Isoleucine | I或Ile |
亮氨酸 | Leucine | L或Leu |
赖氨酸 | Lysine | K或Lys |
蛋氨酸 | Methionine | M或Met |
苯丙氨酸 | Phenylalanine | F或Phe |
脯氨酸 | Proline | P或Pro |
丝氨酸 | Serine | S或Ser |
苏氨酸 | Threonine | T或Thr |
色氨酸 | Tryptophan | W或Trp |
酪氨酸 | Tyrosine | Y或Tyr |
缬氨酸 | Valine | V或Val |
Claims (9)
- 半胱氨酸改造的抗体-毒素偶联物,其特征在于:抗体为半胱氨酸定点***抗体,所述半胱氨酸***位点包含选自以下3个***位点的一个或多个位点:kappa/λ轻链恒定区Kabat编号第205位、轻链恒定区Kabat编号第206或IgG抗体重链恒定区Kabat编号第439位。
- 如权利要求1所述的半胱氨酸改造的抗体-毒素偶联物,其特征在于:所述半胱氨酸***位点氨基酸序列包含以下3个序列的一个或多个:LC-205ins:GLSSPCVTKSF、LC-206ins:GLSSPVCTKSF或HC-439ins:TQKSLSCLSPGK,其中,C为目标抗体轻链205位或206位或重链第439位***的半胱氨酸。
- 如权利要求1所述的半胱氨酸改造的抗体-毒素偶联物,其特征在于:高活性细胞毒素通过连接子与***的半胱氨酸游离巯基进行定点偶联,连接子与***的半胱氨酸偶联的抗体轻链氨基酸序列为:GLSSPCVTKSF和GLSSPVCTKSF;连接子与***的半胱氨酸偶联的抗体重链氨基酸序列为:TQKSLSCLSPGK;其中,C为目标抗体轻链205位或206位或重链第439位***的半胱氨酸。
- 如权利要求1所述的半胱氨酸改造的抗体-毒素偶联物,其特征在于:所述抗体轻链包括kappa或λ同种型。
- 如权利要求1所述的半胱氨酸改造的抗体-毒素偶联物,其特征在于:所述抗体重链包括IgG1、IgG2、IgG3或IgG4同种型。
- 如权利要求1所述的半胱氨酸改造的抗体-毒素偶联物,其特征在于:所述半胱氨酸包含巯基。
- 如权利要求5所述的半胱氨酸改造的抗体-毒素偶联物,其特征在于:所述巯基能够进行化学偶联。
- 如权利要求1所述的半胱氨酸改造的抗体-毒素偶联物,其特征在于:通过连接子与半胱氨酸***突变的游离巯基进行定点偶联的高活性细胞毒素选自:MMAE、MMAF、PBD、SN-38或Dox及其类似物。
- 一种如权利要求1所述的半胱氨酸改造的抗体-毒素偶联物的制备方法,其特征在于:定点偶联步骤为:首先使用还原剂还原抗体,解除抗体上改 造的半胱氨酸残基上的屏蔽,并通过阳离子交换层析或超滤换液等方式去除DTT与屏蔽物;然后使用氧化剂氧化抗体,使抗体的链间二硫键重新连接;最后加入Linker-drug与胱氨酸残基上的游离巯基偶联,并通过阳离子交换层析或超滤换液等方式去除未偶联上抗体分子Linker-drug。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3039559A CA3039559A1 (en) | 2016-10-08 | 2017-09-30 | Cysteine modified antibody-drug conjugate and preparation method thereof |
US16/339,719 US11484605B2 (en) | 2016-10-08 | 2017-09-30 | Cysteine modified antibody-drug conjugate and preparation method thereof |
IL265838A IL265838B2 (en) | 2016-10-08 | 2017-09-30 | Conjugation of an antibody with a drug modified by cysteine and a method for its preparation |
KR1020227044769A KR102579211B1 (ko) | 2016-10-08 | 2017-09-30 | 시스테인 개조된 항체-약물 접합체(Cysteine modified antibody-drug conjugate) 및 그의 제조 방법 |
AU2017340314A AU2017340314B2 (en) | 2016-10-08 | 2017-09-30 | Cysteine modified antibody-drug conjugate and preparation method thereof |
SG11201903084UA SG11201903084UA (en) | 2016-10-08 | 2017-09-30 | Cysteine modified antibody-drug conjugate and preparation method thereof |
EP17857845.6A EP3524273A4 (en) | 2016-10-08 | 2017-09-30 | CYSTEIN-MODIFIED ANTIBODY-ACTIVE SUBSTANCE CONJUGATE AND PRODUCTION METHOD THEREFOR |
JP2019540482A JP6998386B2 (ja) | 2016-10-08 | 2017-09-30 | システイン改変抗体-毒素複合体及びその製造方法 |
RU2019113758A RU2762594C2 (ru) | 2016-10-08 | 2017-09-30 | Конъюгат "цистеин-модифицированное антитело-лекарственное средство" и способ его получения |
KR1020197013122A KR102480873B1 (ko) | 2016-10-08 | 2017-09-30 | 시스테인 개조된 항체-약물 접합체(Cysteine modified antibody-drug conjugate) 및 그의 제조 방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610876568.9 | 2016-10-08 | ||
CN201610876568 | 2016-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018064964A1 true WO2018064964A1 (zh) | 2018-04-12 |
Family
ID=61533952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/104706 WO2018064964A1 (zh) | 2016-10-08 | 2017-09-30 | 半胱氨酸改造的抗体-毒素偶联物及其制备方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11484605B2 (zh) |
EP (1) | EP3524273A4 (zh) |
JP (1) | JP6998386B2 (zh) |
KR (2) | KR102480873B1 (zh) |
CN (2) | CN107789630A (zh) |
AU (1) | AU2017340314B2 (zh) |
CA (1) | CA3039559A1 (zh) |
IL (1) | IL265838B2 (zh) |
RU (1) | RU2762594C2 (zh) |
SG (1) | SG11201903084UA (zh) |
WO (1) | WO2018064964A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020204250A1 (en) * | 2019-05-20 | 2020-12-10 | Mabplex International Co., Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7153082B2 (ja) * | 2017-06-20 | 2022-10-13 | バイリ-バイオ(チェンドゥ)ファーマスーティカル シーオー.,エルティーディー. | システイン改変抗体-毒素複合体(tdc)の部位特異的結合サイトのスクリーニング |
CN110872339A (zh) * | 2018-08-30 | 2020-03-10 | 中国人民解放军军事科学院军事医学研究院 | 含有芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
WO2024088283A1 (zh) * | 2022-10-26 | 2024-05-02 | 同润生物医药(上海)有限公司 | 人源化的l1cam抗体药物偶联物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101065151A (zh) * | 2004-09-23 | 2007-10-31 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
CN102770456A (zh) * | 2009-12-04 | 2012-11-07 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
WO2015157595A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Conjugated compounds comprising cysteine-engineered antibodies |
CN105143271A (zh) * | 2013-02-08 | 2015-12-09 | Irm责任有限公司 | 用于修饰抗体以制备免疫缀合物的特定位点 |
WO2016131769A2 (en) * | 2015-02-16 | 2016-08-25 | Lonza Ltd | Antibodies |
CN106467575A (zh) * | 2015-08-18 | 2017-03-01 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体-毒素偶联物 |
CN106866822A (zh) * | 2016-12-25 | 2017-06-20 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体‑毒素偶联物 |
US20170216452A1 (en) * | 2015-11-30 | 2017-08-03 | Pfizer Inc. | Antibodies and antibody fragments for site-specific conjugation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2683568A1 (en) * | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
PE20090481A1 (es) * | 2007-07-16 | 2009-05-18 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
NZ584514A (en) * | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
EP3269737B1 (en) * | 2008-01-31 | 2024-06-19 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
-
2017
- 2017-09-29 CN CN201710910870.6A patent/CN107789630A/zh active Pending
- 2017-09-29 CN CN202311413663.1A patent/CN117398475A/zh active Pending
- 2017-09-30 WO PCT/CN2017/104706 patent/WO2018064964A1/zh unknown
- 2017-09-30 AU AU2017340314A patent/AU2017340314B2/en active Active
- 2017-09-30 IL IL265838A patent/IL265838B2/en unknown
- 2017-09-30 EP EP17857845.6A patent/EP3524273A4/en active Pending
- 2017-09-30 KR KR1020197013122A patent/KR102480873B1/ko active IP Right Grant
- 2017-09-30 SG SG11201903084UA patent/SG11201903084UA/en unknown
- 2017-09-30 CA CA3039559A patent/CA3039559A1/en active Pending
- 2017-09-30 RU RU2019113758A patent/RU2762594C2/ru active
- 2017-09-30 KR KR1020227044769A patent/KR102579211B1/ko active IP Right Grant
- 2017-09-30 US US16/339,719 patent/US11484605B2/en active Active
- 2017-09-30 JP JP2019540482A patent/JP6998386B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101065151A (zh) * | 2004-09-23 | 2007-10-31 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
CN102770456A (zh) * | 2009-12-04 | 2012-11-07 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
CN105143271A (zh) * | 2013-02-08 | 2015-12-09 | Irm责任有限公司 | 用于修饰抗体以制备免疫缀合物的特定位点 |
WO2015157595A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Conjugated compounds comprising cysteine-engineered antibodies |
WO2016131769A2 (en) * | 2015-02-16 | 2016-08-25 | Lonza Ltd | Antibodies |
CN106467575A (zh) * | 2015-08-18 | 2017-03-01 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体-毒素偶联物 |
US20170216452A1 (en) * | 2015-11-30 | 2017-08-03 | Pfizer Inc. | Antibodies and antibody fragments for site-specific conjugation |
CN106866822A (zh) * | 2016-12-25 | 2017-06-20 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体‑毒素偶联物 |
Non-Patent Citations (1)
Title |
---|
VOYNOV, V. ET AL.: "Design and Application of Antibody Cysteine Variants", BIOCONJUGATE CHEM., vol. 21, no. 2, 21 January 2010 (2010-01-21), pages 385 - 392, XP002598497 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020204250A1 (en) * | 2019-05-20 | 2020-12-10 | Mabplex International Co., Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
AU2020204250B2 (en) * | 2019-05-20 | 2021-04-08 | Mabplex International Co., Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
JP2022512519A (ja) * | 2019-05-20 | 2022-02-07 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 抗体-薬物コンジュゲートの中間体のワンポット合成法による製造プロセス |
JP7167163B2 (ja) | 2019-05-20 | 2022-11-08 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 抗体-薬物コンジュゲートの中間体のワンポット合成法による製造プロセス |
US11717575B2 (en) | 2019-05-20 | 2023-08-08 | Mabplex International Co., Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
Also Published As
Publication number | Publication date |
---|---|
IL265838A (en) | 2019-06-30 |
AU2017340314B2 (en) | 2021-04-29 |
EP3524273A1 (en) | 2019-08-14 |
IL265838B2 (en) | 2024-03-01 |
IL265838B1 (en) | 2023-11-01 |
JP6998386B2 (ja) | 2022-02-10 |
CN117398475A (zh) | 2024-01-16 |
AU2017340314A1 (en) | 2019-05-02 |
KR102480873B1 (ko) | 2022-12-26 |
KR102579211B1 (ko) | 2023-09-15 |
EP3524273A4 (en) | 2020-07-15 |
KR20230003663A (ko) | 2023-01-06 |
CA3039559A1 (en) | 2018-04-12 |
RU2762594C2 (ru) | 2021-12-21 |
CN107789630A (zh) | 2018-03-13 |
SG11201903084UA (en) | 2019-05-30 |
US11484605B2 (en) | 2022-11-01 |
RU2019113758A (ru) | 2020-11-09 |
JP2019533017A (ja) | 2019-11-14 |
US20200129635A1 (en) | 2020-04-30 |
RU2019113758A3 (zh) | 2020-12-25 |
KR20190065374A (ko) | 2019-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108853514B (zh) | 具有两种不同药物的抗体药物偶联物 | |
CN108452321B (zh) | 一种带酸性自稳定接头的抗体-药物偶联物 | |
JP2024096335A (ja) | 親水性抗体-薬物コンジュゲート | |
TWI819474B (zh) | 細胞毒性苯并二氮呯衍生物 | |
WO2018064964A1 (zh) | 半胱氨酸改造的抗体-毒素偶联物及其制备方法 | |
CN111051330A (zh) | 抗体-药物缀合物的改进制备方法 | |
CA3072754A1 (en) | 6-amino-7,9-dihydro-8h-purin-8-one derivatives as immunostimulant toll-like receptor 7 (tlr7) agonists | |
JP2020531469A (ja) | 三環式基を有するトル様受容体7(tlr7)アゴニスト、そのコンジュゲート、ならびにそれらの方法および使用 | |
JP2020531474A (ja) | トル様受容体7(tlr7)アゴニストとしての6−アミノ−7,9−ジヒドロ−8h−プリン−8−オン誘導体 | |
JP2020531472A (ja) | 免疫刺激因子トル様受容体7(tlr7)アゴニストとしての、6−アミノ−7,9−ジヒドロ−8h−プリン−8−オン誘導体 | |
KR20180030993A (ko) | 항체-약물 접합체 중의 공유결합 링커 및 이의 제조방법 및 사용방법 | |
WO2020125546A1 (zh) | 一种用于抗体药物偶联物的连接子及其应用 | |
TW201400131A (zh) | 自行穩定之接合劑共軛物 | |
JP2024503074A (ja) | カンプトテシン抗体-薬物コンジュゲート及びその使用方法 | |
JP2023011567A (ja) | システイン改変抗体-毒素複合体(tdc)の部位特異的結合サイトのスクリーニング | |
CN114173825A (zh) | 抗体-药物偶联物及其在治疗中的应用 | |
CN112604004B (zh) | 一类抗人egfr抗体药物偶联物及其制备方法与应用 | |
JP7356677B2 (ja) | 複合体 | |
WO2024067754A1 (zh) | 一种带有高稳定性亲水连接单元的奥瑞他汀类药物及其偶联物 | |
TW202421202A (zh) | 抗cd33抗體和抗cd33抗體-藥物偶聯物及其用途 | |
CN117298291A (zh) | Fc结合肽偶联物、靶向TROP2的定点偶联ADC及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17857845 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3039559 Country of ref document: CA Ref document number: 2019540482 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017340314 Country of ref document: AU Date of ref document: 20170930 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197013122 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017857845 Country of ref document: EP Effective date: 20190508 |